Evidence map›Paper›PMID 25565998›Full record

ArticleFrontiers in behavioral neuroscience2014

Differential responses to acute administration of a new 5-HT7-R agonist as a function of adolescent pre-treatment: phMRI and immuno-histochemical study.

Luisa Altabella, Marco Sbriccoli, Francesca Zoratto, Anna Poleggi, Ramona Vinci, Enza Lacivita, Marcello Leopoldo, Giovanni Laviola, Franco Cardone, Rossella Canese and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Luisa AltabellaDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Marco SbriccoliDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Francesca ZorattoDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy ; Bambino Gesù Children's Hospital IRCCS Rome, Italy.
Anna PoleggiDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Ramona VinciDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy ; Bambino Gesù Children's Hospital IRCCS Rome, Italy.
Enza LacivitaDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro" Bari, Italy.
Marcello LeopoldoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro" Bari, Italy.
Giovanni LaviolaDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Franco CardoneDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Rossella CaneseDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Walter AdrianiDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità Rome, Italy.
Istituto Superiore di Sanità · ITUniversity of Bari Aldo Moro · ITBambino Gesù Children's Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LP-211 is a new, selective agonist of serotonin (5-hydroxytryptamine, 5-HT) receptor 7 (5-HT7-R), which is part of a neuro-transmission system with a proposed role in neural plasticity and in mood, cognitive and sleep regulation. Adolescent subchronic LP-211 treatment produces some persisting changes in rats' forebrain structural and functional parameters. Here, using pharmacological MRI (phMRI), we investigated the effect of acute administration with LP-211 (10 mg/kg i.p.), or vehicle, to adult rats previously exposed to the same drug (0.25 mg/kg/day for 5 days), or vehicle, during adolescence (44-48 post-natal days); histology and immuno-histochemistry were performed ex vivo to evaluate neuro-anatomical and physiological long-term adaptation to pharmacological pre-treatment. The phMRI signal reveals forebrain areas (i.e., hippocampus, orbital prefrontal cortex), activated in response to LP-211 challenge independently of adolescent pre-treatment. In septum and nucleus accumbens, sensitized activation was found in adolescent pre-treated rats but not in vehicle-exposed controls. Immuno-histochemical analyses showed marked differences in septum as long-term consequence of the adolescent pre-treatment: increased level of 5-HT7-R, increased number of 5-HT7-R positive cells, and enhanced astrocyte activation. For nucleus accumbens, immuno-histochemical analyses did not reveal any difference between adolescent pre-treated rats and vehicle-exposed controls. In conclusion, subchronic LP-211 administration during adolescence is able to induce persistent physiological changes in the septal 5-HT7-R expression and astrocyte response that can still be observed in adulthood. Data shed new insights into roles of 5-HT7-R for normal and pathologic behavioral regulations.

Indexed as

hippocampuslimbic/cortical loopLP-211nucleus accumbensPh-MRIseptum

Identifiers

PMID25565998
PMCPMC4267273
OpenAlexW2013081996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.